Patents Assigned to APTARION biotech AG
  • Patent number: 12188021
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.
    Type: Grant
    Filed: November 7, 2022
    Date of Patent: January 7, 2025
    Assignee: APTARION biotech AG
    Inventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
  • Publication number: 20240384275
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3?[SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.
    Type: Application
    Filed: November 7, 2022
    Publication date: November 21, 2024
    Applicant: APTARION biotech AG
    Inventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
  • Patent number: 11634741
    Abstract: The present invention is related to a method for adding one or more L-nucleotides to the 3?end of a first L-nucleic acid, wherein the method comprises the step of reacting the one or more L-nucleotides with the first L-nucleic acid in the presence of a protein comprising a mutant enzymatic activity exhibiting moiety, wherein the enzymatic activity is capable of adding one or more L-nucleotides to the 3? end of the first L-nucleic acid, wherein the mutant enzymatic activity exhibiting moiety comprises an amino acid sequence, wherein the amino acids of the amino acid sequence are D-amino acids, wherein the mutant enzymatic activity exhibiting moiety is a variant of an enzymatic activity exhibiting moiety, wherein the enzymatic activity exhibiting moiety consists of an amino acid sequence according to SEQ ID NO: 15 and wherein the amino acids of the amino acid sequence according to SEQ ID NO: 15 are D-amino acids, wherein the amino acid sequence of the mutant enzymatic activity exhibiting moiety differs from the
    Type: Grant
    Filed: November 20, 2014
    Date of Patent: April 25, 2023
    Assignee: Aptarion biotech AG
    Inventors: Andreas Pech, Florian Jarosch, Michael Jahnz, Sven Klussmann, Ralf David
  • Patent number: 11492625
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.
    Type: Grant
    Filed: March 15, 2020
    Date of Patent: November 8, 2022
    Assignee: APTARION biotech AG
    Inventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
  • Publication number: 20210403913
    Abstract: The present invention is related to an L-nucleic acid molecule capable of binding to human CXCL8, wherein the L-nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5?-GG A AGU ACGUGGA AAGCCRA(Xu)RAGUGUGUCCCG-3? [SEQ. ID. NO: 27], wherein Xu is U or absent.
    Type: Application
    Filed: November 12, 2019
    Publication date: December 30, 2021
    Applicant: Aptarion Biotech AG
    Inventors: Kai Hohlig, Axel Vater, Werner Purschke, Dirk Zboralski, Christian Maasch
  • Publication number: 20210163946
    Abstract: The present invention is related to a nucleic acid molecule capable of binding to human C5a, wherein the nucleic acid molecule comprises a central stretch of nucleotides, wherein the central stretch of nucleotides comprises a nucleotide sequence of 5? AUGn1GGUGKUn2n3RGGGHUGUKGGGn4Gn5CGACGCA 3? [SEQ ID NO: 61], wherein n1 is U or dU, n2 is G or dG, n3 is A or dA, n4 is U or dU, n5 is U or dU and G, A, U, C, H, K, and R are ribonucleotides, and dU, dG and dA are 2?-deoxyribonucleotides.
    Type: Application
    Filed: March 15, 2020
    Publication date: June 3, 2021
    Applicant: Aptarion Biotech AG
    Inventors: Kai Hohlig, Axel Vater, Klaus Buchner, Christian Maasch, Sven Klussmann
  • Patent number: 11015178
    Abstract: The present invention is related to a method for adding one or more L-nucleotides to the 3? end of a first L-nucleic acid, wherein the method comprises the step of reacting the one or more L-nucleotides with the first L-nucleic acid in the presence of a protein comprising an enzymatic activity exhibiting moiety, wherein the enzymatic activity is capable of adding one or more L-nucleotides to the 3? end of the first L-nucleic acid.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: May 25, 2021
    Assignee: APTARION biotech AG
    Inventors: Andreas Pech, Ralf David, Florian Jarosch, Michael Jahnz, Sven Klussmann